Envoy Medical, Inc. Files Amendment No. 2 to S-1 Registration Statement

TL;DR

<b>Envoy Medical, Inc. has filed an amendment to its S-1 registration statement, indicating ongoing efforts to register securities.</b>

AI Summary

Envoy Medical, Inc. (COCHW) filed a Amended IPO Registration (S-1/A) with the SEC on April 5, 2024. Envoy Medical, Inc. filed an amendment (No. 2) to its S-1 Registration Statement on April 5, 2024. The filing pertains to the registration of securities under the Securities Act of 1933. The company's principal executive offices are located at 4875 White Bear Parkway, White Bear Lake, MN 55110. The IRS Employer Identification Number for Envoy Medical, Inc. is 86-1369123. The company was formerly known as Anzu Special Acquisition Corp I, with a name change date of January 15, 2021.

Why It Matters

For investors and stakeholders tracking Envoy Medical, Inc., this filing contains several important signals. This S-1/A filing signifies that Envoy Medical is actively pursuing a public offering or has ongoing registration requirements for its securities. The amendment suggests updates or revisions to previously submitted information, potentially related to financial status, business operations, or offering details.

Risk Assessment

Risk Level: low — Envoy Medical, Inc. shows low risk based on this filing. The filing is a routine S-1/A amendment, which typically involves procedural updates rather than immediate material events, thus posing a low immediate risk.

Analyst Insight

Monitor future filings for details on the proposed offering, financial performance, and business developments of Envoy Medical, Inc.

Key Numbers

• 333-276590 — Registration Number (SEC Registration Number)
• 86-1369123 — IRS Employer Identification Number (Filer's EIN)
• 20210115 — Date of Name Change (Former Company Name Change)
• April 5, 2024 — Filing Date (Amendment Date)

Key Players & Entities

• Envoy Medical, Inc. (company) — Registrant
• Brent T. Lucas (person) — Chief Executive Officer
• David P. Slotkin (person) — Copies to Counsel
• Andrew P. Campbell (person) — Copies to Counsel
• Morrison & Foerster LLP (company) — Counsel
• Anzu Special Acquisition Corp I (company) — Former Company Name
• 333-276590 (regulator) — Registration Number
• April 5, 2024 (date) — Filing Date

FAQ

Industry Context

Envoy Medical, Inc. operates in the orthopedic, prosthetic, and surgical appliances & supplies industry (SIC code 3842).

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of new securities offerings.

What Investors Should Do

1. Review the full S-1/A filing for specific details on the securities being registered and any updated financial or business information.
2. Track future SEC filings from Envoy Medical, Inc. for updates on their offering status and business progress.
3. Research the company's market and competitive landscape within the medical device sector.

Key Dates

• 2024-04-05: Amendment No. 2 Filing — Updates and revisions to the S-1 registration statement.
• 2021-01-15: Name Change — Former company name Anzu Special Acquisition Corp I changed to Envoy Medical, Inc.

Year-Over-Year Comparison

This is an amendment to a previous S-1 filing, indicating updates or corrections to the initial registration statement.

Key Financial Figures

• $0.0001 — 103 shares of our Class A common stock, $0.0001 par value per share (" Class A Common S
• $10.00 — fering (" IPO ") of units at a price of $10.00 per unit, with each unit consisting of
• $0.001 — Anzu's Class B common stock, par value $0.001 per share (the " Anzu Class B Common St
• $0.002 — n connection with the IPO at a price of $0.002 per share; (iv) up to 869,565 shares o
• $11.50 — er share and have a conversion price of $11.50 per share; and (v) up to 869,565 share
• $10.46 — e of Class A Common Stock at a price of $10.46 per share, subject to adjustment. We wi
• $203.4 million — ct to adjustment. We will receive up to $203.4 million from the exercise of the Warrants, assu
• $10 — Class A Common Stock exceeds $11.50 and $10.46, warrantholders may exercise their P
• $25 m — for an aggregate price of approximately $25 million, which represented approximately
• $10.50 — Class A Common Stock equals or exceeds $10.50 per share (as adjusted for stock splits
• $5 — s A Common Stock as of April 4, 2024 of $5.86, the Sponsor may experience potentia
• $5.858 — ay experience potential profit of up to $5.858 per share (or approximately $11.7 milli
• $11.7 million — p to $5.858 per share (or approximately $11.7 million in the aggregate based on the Sponsor h
• $5.86 — g price of our Class A Common Stock was $5.86 and the closing price for our Public Wa
• $0.21 — osing price for our Public Warrants was $0.21. See the section entitled " Risk Facto

Filing Documents

• ea0203133-01.htm (S-1/A) — 5790KB
• ea020313301ex23-1_envoy.htm (EX-23.1) — 2KB
• tenvoy_logo.jpg (GRAPHIC) — 43KB
• timage_001.jpg (GRAPHIC) — 361KB
• timage_002.jpg (GRAPHIC) — 156KB
• timage_003.jpg (GRAPHIC) — 316KB
• timage_004.jpg (GRAPHIC) — 92KB
• ex23-1_001.jpg (GRAPHIC) — 2KB
• 0001213900-24-030821.txt (&nbsp;) — 16713KB
• coch-20231231.xsd (EX-101.SCH) — 72KB
• coch-20231231_cal.xml (EX-101.CAL) — 36KB
• coch-20231231_def.xml (EX-101.DEF) — 372KB
• coch-20231231_lab.xml (EX-101.LAB) — 650KB
• coch-20231231_pre.xml (EX-101.PRE) — 385KB
• ea0203133-01_htm.xml (XML) — 2059KB

USE OF PROCEEDS

USE OF PROCEEDS 35 DETERMINATION OF OFFERING PRICE 36 MARKET PRICE, TICKER SYMBOL AND DIVIDEND INFORMATION 37

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 63 MANAGEMENT 76

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 83 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 86 BENEFICIAL OWNERSHIP OF SECURITIES 91 SELLING SECURITYHOLDERS 93 DESCRIPTION OF OUR SECURITIES 96 PLAN OF DISTRIBUTION 106 LEGAL MATTERS 109 EXPERTS 109 WHERE YOU CAN FIND MORE INFORMATION 109 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 You should rely only on the information provided in this prospectus, as well as the information incorporated by reference into this prospectus and any applicable prospectus supplement. Neither we nor the Selling Securityholders have authorized anyone to provide you with different information. Neither we nor the Selling Securityholders are making an offer of these securities in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus or any applicable prospectus supplement is accurate as of any date other than the date of the applicable document. Since the date of this prospectus and the documents incorporated by reference into this prospectus, our business, financial condition, results of operations and prospects may have changed. i Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S -1 that we filed with the U.S. Securities and Exchange Commission (the " SEC ") using the "shelf" registration process. Under this shelf registration process, the Selling Securityholders may, from time to time, sell up to 3,874,394 Shortfall Warrants and up to 21,206,360 shares of Class A Common Stock, consisting of: (i) up to 3,874,394 shares of Class A Common Stock that are issuable upon the exercise of 3,874,394 Shortfall Warrants issued to the Meteora FPA Parties for no additional consideration pursuant to the Forward Purchase Agreement; (ii) up to 2,173,913 shares of Class A Common Stock issuable upon conversion of 2,500,000 shares of Series A Preferred Stock, which were issued to the Sponsor concurrently with the Closing i

View Full Filing

View this S-1/A filing on SEC EDGAR